Showing results (101-110 of 251) with videos related to
Sort By:
Pageof 26
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 2, 2026
Prognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancerToshiya Fujisaki, Tateaki Naito, Satomi Kumaki, et al.Cancer Science|January 29, 2011
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reportsTakehito Shukuya, Toshiaki Takahashi, Rieko Kaira, et al.Trials|April 2, 2020
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET studyMototsugu Shimokawa, Kaname Nosaki, Takashi Seto, et al.Annals of Nuclear Medicine|December 22, 2010
18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumorsKyoichi Kaira, Haruyasu Murakami, Satoru Miura, et al.Cancer Chemotherapy and Pharmacology|February 11, 2020
Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicityTakahisa Kawamura, Chiyo K Imamura, Hirotsugu Kenmotsu, et al.Cancer Chemotherapy and Pharmacology|March 25, 2009
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumorsNoboru Yamamoto, Tomohide Tamura, Nobuyuki Yamamoto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2010
A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancerChiharu Tanai, Nobuyuki Yamamoto, Yuichiro Ohe, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 11, 2021
Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911LHiroaki Akamatsu, Haruyasu Murakami, Hideyuki Harada, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2005
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisolNoboru Yamamoto, Tomohide Tamura, Haruyasu Murakami, et al.Investigational New Drugs|February 22, 2019
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutationsMakoto Nishio, Haruyasu Murakami, Yuichiro Ohe, et al.Pageof 26